Skip navigation
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSubrahmanyam, Marti G.-
dc.contributor.authorTang, Dragon Yongjun-
dc.contributor.authorWang, Sarah Qian-
dc.date.accessioned2012-01-09T18:11:59Z-
dc.date.available2012-01-09T18:11:59Z-
dc.date.issued2012-01-09T18:11:59Z-
dc.identifier.urihttp://hdl.handle.net/2451/31421-
dc.description.abstractConcerns have been raised, especially since the global financial crisis, about whether trading in credit default swaps (CDS) increases the credit risk of the reference entities. This study examines this issue by quantifying the impact of CDS trading on the credit risk of firms. We use a unique, comprehensive sample covering 901 CDS introductions on North American corporate issuers between June 1997 and April 2009 to address this question. We present evidence that the probability of a credit downgrade and of bankruptcy both increase after the inception of CDS trading. The effect is robust to controlling for the endogeneity of CDS introduction, i.e., the possibility that firms selected for CDS trading are more likely to suffer a subsequent deterioration in creditworthiness. We show that the CDS-protected lenders’ reluctance to restructure is the most likely cause of the increase in credit risk. We present evidence that firms with relatively large amounts of CDS contracts outstanding, and those with “No Restructuring” contracts, are more likely to be adversely affected by CDS trading. We also document that CDS trading increases the level of participation of bank lenders to the firm. Our findings are broadly consistent with the predictions of the “empty creditor” model of Bolton and Oehmke (2011).en
dc.language.isoen_USen
dc.relation.ispartofseriesFIN-11-046-
dc.titleDoes the Tail Wag the Dog? The Effect of Credit Default Swaps on Credit Risken
dc.typeWorking Paperen
dc.authorid-ssrn738en
Appears in Collections:Finance Working Papers

Files in This Item:
File Description SizeFormat 
CDSandBankruptcy17Dec2011.pdfMain Working Paper284.14 kBAdobe PDFView/Open


Items in FDA are protected by copyright, with all rights reserved, unless otherwise indicated.